Research and Clinical Progress of Therapeutic Tumor Vaccines
Therapeutic cancer vaccines are a new growth point of biomedicine with broad industrial prospects in the post-COVID-19 era. Many large international pharmaceutical companies and emerging biotechnology companies are deploying different tumor therapeutic cancer vaccine projects, focusing on promoting...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/7/672 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850071181585022976 |
|---|---|
| author | Chunyan Dong Zhuang Li Dejiang Tan Huimin Sun Jinghui Liang Dexian Wei Yiyang Zheng Linyu Zhang Sihan Liu Yu Zhang Junzhi Wang Qing He |
| author_facet | Chunyan Dong Zhuang Li Dejiang Tan Huimin Sun Jinghui Liang Dexian Wei Yiyang Zheng Linyu Zhang Sihan Liu Yu Zhang Junzhi Wang Qing He |
| author_sort | Chunyan Dong |
| collection | DOAJ |
| description | Therapeutic cancer vaccines are a new growth point of biomedicine with broad industrial prospects in the post-COVID-19 era. Many large international pharmaceutical companies and emerging biotechnology companies are deploying different tumor therapeutic cancer vaccine projects, focusing on promoting their clinical transformation, and the vaccine industry has strong momentum for development. Such vaccines are also the core engine and pilot site for the development of new vaccine targets, new vectors, new adjuvants, and new technologies, which play a key role in promoting the innovation and development of vaccines. Various therapeutic cancer vaccines, such as viral vector vaccines, bacterial vector vaccines, cell vector vaccines, peptide vaccines, and nucleic acid vaccines, have all been applied in clinical research. With the continuous development of technology, therapeutic cancer vaccines are evolving towards the trends of precise antigens, efficient carriers, diversified adjuvants, and combined applications. For instance, the rapidly advancing mRNA-4157 vaccine is a typical representative that combines personalized antigens with efficient delivery vectors (lipid nanoparticles, LNPs), and it also shows synergistic advantages in melanoma patients treated in combination with immune checkpoint inhibitors. In this article, we will systematically discuss the current research and development status and clinical research progress of various therapeutic cancer vaccines. |
| format | Article |
| id | doaj-art-5dc7b8c91a3b4b0b8cb680288bf841a9 |
| institution | DOAJ |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-5dc7b8c91a3b4b0b8cb680288bf841a92025-08-20T02:47:22ZengMDPI AGVaccines2076-393X2025-06-0113767210.3390/vaccines13070672Research and Clinical Progress of Therapeutic Tumor VaccinesChunyan Dong0Zhuang Li1Dejiang Tan2Huimin Sun3Jinghui Liang4Dexian Wei5Yiyang Zheng6Linyu Zhang7Sihan Liu8Yu Zhang9Junzhi Wang10Qing He11State Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaDepartment of Experimental Pharmacology and Toxicology, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaState Key Laboratory of Drug Regulatory Sciences, National Institutes for Food and Drug Control, Beijing 102629, ChinaTherapeutic cancer vaccines are a new growth point of biomedicine with broad industrial prospects in the post-COVID-19 era. Many large international pharmaceutical companies and emerging biotechnology companies are deploying different tumor therapeutic cancer vaccine projects, focusing on promoting their clinical transformation, and the vaccine industry has strong momentum for development. Such vaccines are also the core engine and pilot site for the development of new vaccine targets, new vectors, new adjuvants, and new technologies, which play a key role in promoting the innovation and development of vaccines. Various therapeutic cancer vaccines, such as viral vector vaccines, bacterial vector vaccines, cell vector vaccines, peptide vaccines, and nucleic acid vaccines, have all been applied in clinical research. With the continuous development of technology, therapeutic cancer vaccines are evolving towards the trends of precise antigens, efficient carriers, diversified adjuvants, and combined applications. For instance, the rapidly advancing mRNA-4157 vaccine is a typical representative that combines personalized antigens with efficient delivery vectors (lipid nanoparticles, LNPs), and it also shows synergistic advantages in melanoma patients treated in combination with immune checkpoint inhibitors. In this article, we will systematically discuss the current research and development status and clinical research progress of various therapeutic cancer vaccines.https://www.mdpi.com/2076-393X/13/7/672therapeutic tumor vaccinesclinical progress |
| spellingShingle | Chunyan Dong Zhuang Li Dejiang Tan Huimin Sun Jinghui Liang Dexian Wei Yiyang Zheng Linyu Zhang Sihan Liu Yu Zhang Junzhi Wang Qing He Research and Clinical Progress of Therapeutic Tumor Vaccines Vaccines therapeutic tumor vaccines clinical progress |
| title | Research and Clinical Progress of Therapeutic Tumor Vaccines |
| title_full | Research and Clinical Progress of Therapeutic Tumor Vaccines |
| title_fullStr | Research and Clinical Progress of Therapeutic Tumor Vaccines |
| title_full_unstemmed | Research and Clinical Progress of Therapeutic Tumor Vaccines |
| title_short | Research and Clinical Progress of Therapeutic Tumor Vaccines |
| title_sort | research and clinical progress of therapeutic tumor vaccines |
| topic | therapeutic tumor vaccines clinical progress |
| url | https://www.mdpi.com/2076-393X/13/7/672 |
| work_keys_str_mv | AT chunyandong researchandclinicalprogressoftherapeutictumorvaccines AT zhuangli researchandclinicalprogressoftherapeutictumorvaccines AT dejiangtan researchandclinicalprogressoftherapeutictumorvaccines AT huiminsun researchandclinicalprogressoftherapeutictumorvaccines AT jinghuiliang researchandclinicalprogressoftherapeutictumorvaccines AT dexianwei researchandclinicalprogressoftherapeutictumorvaccines AT yiyangzheng researchandclinicalprogressoftherapeutictumorvaccines AT linyuzhang researchandclinicalprogressoftherapeutictumorvaccines AT sihanliu researchandclinicalprogressoftherapeutictumorvaccines AT yuzhang researchandclinicalprogressoftherapeutictumorvaccines AT junzhiwang researchandclinicalprogressoftherapeutictumorvaccines AT qinghe researchandclinicalprogressoftherapeutictumorvaccines |